An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical Benefit Rate defined as percentage of subjects with a complete response, partial response, or stable disease for at least 6 months
Every 8 weeks according to CT scan
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Brazil: Ministry of Health
CA187-016
NCT01068704
June 2010
December 2010
Name | Location |
---|---|
Yakima Valley Memorial Hospital/North Star Lodge | Yakima, Washington 98902 |
Texas Oncology-Abilene | Abilene, Texas 79606 |
Texas Oncology-Beaumont | Beaumont, Texas 77702 |
Us Oncology Central Pharmacy | Fort Worth, Texas 76177 |